This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1987 Oct;71(10):991-2.

Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia

J L Harousseau, P Hurteloup, J Reiffers, F Rigal-Huguet, M Hayat, P Dufour, P Y Le Prise, M Monconduit, J Jaubert, Y Carcassonne

PMID: 3477319

Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia

J L Harousseau et al. Cancer Treat Rep. 1987 Oct.

. 1987 Oct;71(10):991-2.

Authors

J L Harousseau, P Hurteloup, J Reiffers, F Rigal-Huguet, M Hayat, P Dufour, P Y Le Prise, M Monconduit, J Jaubert, Y Carcassonne

PMID: 3477319

No abstract available

PubMed Disclaimer

Similar articles

Preliminary results in secondary acute non-lymphocytic leukemia (ANLL) treated with Idarubicin.
Parmentier C, Finaud M, Schlumberger M, Morardet N, Berger R, Bayle C, Carde P, Hurteloup P, Hayat M. Parmentier C, et al. Nouv Rev Fr Hematol (1978). 1985;27(6):393-5. Nouv Rev Fr Hematol (1978). 1985. PMID: 3867854
4-Demethoxydaunorubicin (idarubicin) in refractory or relapsed acute leukemias.
Carella AM, Santini G, Martinengo M, Marmont AM. Carella AM, et al. Haematologica. 1984 Nov-Dec;69(6):767-8. Haematologica. 1984. PMID: 6441755 No abstract available.
[Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
Liu Y, Ke XY, Ma J, Shen ZX, Zhang XH, Du X, Zhao YM, Lv JQ, Zhan ZM, Zeng XY, Xu XH, Lu ZS. Liu Y, et al. Zhonghua Zhong Liu Za Zhi. 2006 Sep;28(9):706-8. Zhonghua Zhong Liu Za Zhi. 2006. PMID: 17274381 Clinical Trial. Chinese.
A review of idarubicin in acute leukemia.
Berman E. Berman E. Oncology (Williston Park). 1993 Oct;7(10):91-8, 104; discussion 104-7. Oncology (Williston Park). 1993. PMID: 8251309 Review.
Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies.
Speth PA, Minderman H, Haanen C. Speth PA, et al. Semin Oncol. 1989 Feb;16(1 Suppl 2):2-9. Semin Oncol. 1989. PMID: 2648580 Review. No abstract available.

See all similar articles

Cited by

A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.
Abraham R, Basser RL, Green MD. Abraham R, et al. Drug Saf. 1996 Dec;15(6):406-29. doi: 10.2165/00002018-199615060-00005. Drug Saf. 1996. PMID: 8968695 Review.
Acute myelogenous leukaemia in children.
Lie SO. Lie SO. Eur J Pediatr. 1989 Feb;148(5):382-8. doi: 10.1007/BF00595892. Eur J Pediatr. 1989. PMID: 2646125 Review.
Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.
Hollingshead LM, Faulds D. Hollingshead LM, et al. Drugs. 1991 Oct;42(4):690-719. doi: 10.2165/00003495-199142040-00010. Drugs. 1991. PMID: 1723369 Review.
The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Li X, Xu S, Tan Y, Chen J. Li X, et al. Cochrane Database Syst Rev. 2015 Jun 3;2015(6):CD010432. doi: 10.1002/14651858.CD010432.pub2. Cochrane Database Syst Rev. 2015. PMID: 26037486 Free PMC article.
Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment.
Hiddemann W, Büchner T. Hiddemann W, et al. Blut. 1990 Mar;60(3):163-71. doi: 10.1007/BF01720270. Blut. 1990. PMID: 2180498 Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Medical
- MedlinePlus Health Information